ClinicalTrials.gg

Program

Digoxin

Also written as “digoxin”, “ZT002 injection, rosuvastatin, digoxin” and “Digoxin (0.25mg)”.

Its studies are mostly in Obesity · Neoplasms · Thalassemia · Carcinoma, Non-Small-Cell Lung · Liver Cirrhosis, led by 25 companies.

Furthest: phase 2, since Jun 1, 201043 company-led studies, 1 open or runningNext primary completion: Dec 5, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim90 open or runningphase 1since Jun 1, 2010Jun 1, 2010none ahead
AstraZeneca30 open or runningphase 1since Jul 8, 2008Jul 8, 2008none ahead
Bristol-Myers Squibb30 open or runningphase 1since Oct 9, 2014Oct 9, 2014none ahead
Astellas Pharma20 open or runningphase 1since Apr 29, 2014Apr 29, 2014none ahead
GlaxoSmithKline20 open or runningphase 1since Mar 28, 2008Mar 28, 2008none ahead
Hoffmann-La Roche20 open or runningphase 1since Jan 9, 2013Jan 9, 2013none ahead
Johnson & Johnson20 open or runningphase 1since Jan 20, 2011Jan 20, 2011none ahead
Merck20 open or runningphase 1since Aug 26, 2024Aug 26, 2024none ahead
Sanofi20 open or runningphase 1since May 19, 2011May 19, 2011none ahead
AbbVie10 open or runningphase 1since Feb 3, 2016Feb 3, 2016none ahead
Beijing QL Biopharmaceutical11 open or runningphase 1since Apr 20, 2026Apr 20, 2026Dec 5, 2026phase 1 · NCT07550816
Biogen10 open or runningphase 1since May 11, 2012May 11, 2012none ahead
cmp-development-llc10 open or runningphase 1since Feb 16, 2019Feb 16, 2019none ahead
CSL10 open or runningphase 1since Nov 16, 2011Nov 16, 2011none ahead
Daiichi Sankyo10 open or runningphase 1since Jan 4, 2012Jan 4, 2012none ahead
Eisai10 open or runningphase 1since Jan 23, 2014Jan 23, 2014none ahead
Eli Lilly10 open or runningphase 1since Dec 16, 2023Dec 16, 2023none ahead
Jiangsu HengRui Medicine10 open or runningphase 1since Mar 17, 2020Mar 17, 2020none ahead
Maruho10 open or runningphase 2since Dec 19, 2014Dec 19, 2014none ahead
Merck KGaA, Darmstadt, Germany10 open or runningphase 1since Sep 23, 2021Sep 23, 2021none ahead
Novo Nordisk10 open or runningphase 1since Feb 3, 2025Feb 3, 2025none ahead
Pfizer10 open or runningphase 1since Jan 27, 2009Jan 27, 2009none ahead
pharmaand10 open or runningphase 1since Mar 30, 2016Mar 30, 2016none ahead
Puma Biotechnology10 open or runningphase 1since Mar 11, 2009Mar 11, 2009none ahead
Takeda10 open or runningphase 1since Apr 20, 2016Apr 20, 2016none ahead

Also a collaborator on its studies: parexel, impact-biomedicines-inc-a-wholly-owned-subsidiary-of-celgene and medpace-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 29 studies since Mar 28, 2008.

  1. Sep 17, 2019Phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT04094519 · 24 enrolled · Moldova, Republic of
  2. Jan 14, 2020Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04231435 · 24 enrolled · United States
  3. Mar 17, 2020Jiangsu HengRui Medicine's first study: phase 1 study in Advanced Solid TumorNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04322552 · 18 enrolled · China
  4. Oct 15, 2020Phase 1 study in HealthyBoehringer Ingelheim · NCT04590937 · 15 enrolled · Germany
  5. Sep 23, 2021Merck KGaA, Darmstadt, Germany's first study: phase 1 study in HealthyNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05064488 · 40 enrolled · Germany
  6. Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741372 · 28 enrolled · Germany
  7. Mar 3, 2023Phase 1 study in Healthy Male SubjectsAstraZeneca · NCT05768360 · 6 enrolled · Germany
  8. Dec 16, 2023Eli Lilly's first study: phase 1 study in ObesityNew to Eli LillyEli Lilly · NCT06186622 · 50 enrolled · United States
  9. Aug 26, 2024Merck's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to MerckMerck · NCT06575933 · 28 enrolled · United States
  10. Oct 1, 2024Phase 1 study in HealthyMerck · NCT06625827 · 24 enrolled · United States
  11. Nov 5, 2024Phase 1 study in Healthy ParticipantsHoffmann-La Roche · NCT06677957 · 19 enrolled · United States
  12. Feb 3, 2025Novo Nordisk's first study: phase 1 study in ThalassemiaNew to Novo NordiskNovo Nordisk · NCT06813924 · 37 enrolled · United States
  13. Aug 5, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07118215 · 62 enrolled · United States
  14. Apr 20, 2026Beijing QL Biopharmaceutical's first study: phase 1 study in OverweightNew to Beijing QL BiopharmaceuticalBeijing QL Biopharmaceutical · NCT07550816 · 60 enrolled · China

Ahead

  1. Dec 5, 2026Primary completion: phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07550816

TargetBeta

“Sodium/potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same 8 targets

ProgramCompanyFurthest phaseStudies
Istaroximerulewindtree-therapeuticsphase 38

Studies

All 43 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07550816Overweight · China1Active, not recruitingBeijing QL BiopharmaceuticalDec 5, 202660
NCT07118215Healthy Volunteers · United States1CompletedBristol-Myers SquibbJun 25, 202662
NCT06813924Thalassemia · United States1CompletedNovo NordiskMay 27, 202537
NCT06677957Healthy Participants · United States1CompletedHoffmann-La RocheDec 30, 202419
NCT06625827Healthy · United States1CompletedMerckJan 22, 202424
NCT06575933Carcinoma, Non-Small-Cell Lung · United States1CompletedMerckOct 28, 202428
NCT06186622Obesity · United States1CompletedEli LillyJul 10, 202450
NCT05768360Healthy Male Subjects · Germany1CompletedAstraZenecaJun 24, 20236
NCT05741372Liver Cirrhosis · Germany–CompletedBoehringer IngelheimDec 18, 202428
NCT05064488Healthy · Germany1CompletedMerck KGaA, Darmstadt, GermanyDec 10, 202140
NCT04590937Healthy · Germany1CompletedBoehringer IngelheimJan 11, 202115
NCT04322552Advanced Solid Tumor · China1CompletedJiangsu HengRui MedicineApr 3, 202118
NCT04231435Healthy Volunteers · United States1CompletedBristol-Myers SquibbFeb 19, 202024
NCT04094519Prostatic Neoplasms · Moldova, Republic of1CompletedAstellas PharmaDec 27, 202024
NCT03909529Drug Drug Interaction · India1Completedcmp-development-llcApr 19, 201928
NCT03307252Healthy · Germany1CompletedBoehringer IngelheimMay 2, 201845
NCT02854527Healthy · Germany1CompletedBoehringer IngelheimNov 11, 201630
NCT02775240Cytomegalovirus (CMV) · United States1CompletedTakedaSep 12, 201618
NCT02740712Neoplasms · Poland1CompletedpharmaandMar 201717
NCT02685462Healthy · United States1CompletedAbbVieFeb 23, 201636
NCT02345304Healthy · Germany1WithdrawnBoehringer IngelheimApr 20150
NCT02333643Cutaneous Warts · Netherlands2CompletedMaruhoAug 201581
NCT02262520N/A - Healthy Subjects1CompletedBristol-Myers SquibbMar 200624
NCT02231931Healthy · Germany1CompletedBoehringer IngelheimJan 1, 201524
NCT02171052Healthy1CompletedBoehringer IngelheimAug 200624
NCT02127034Healthy Subjects · Germany1CompletedAstellas PharmaJun 201426
NCT02055703Healthy Subjects · United States1CompletedEisaiApr 2014195
NCT01765569Melanoma · Belarus, Israel, Korea, Republic of and more1CompletedHoffmann-La RocheJun 201429
NCT01598363Healthy Volunteers · United States1CompletedBiogenJul 31, 201232
NCT01561781Healthy Volunteers · United States1CompletedSanofiJul 201214
NCT01583036Epilepsy · United States1CompletedGlaxoSmithKlineApr 17, 201230
NCT01517399Neoplasms · United States1CompletedDaiichi SankyoAug 201328
NCT01519128Acquired Immunodeficiency Syndrome · Belgium1CompletedJohnson & JohnsonApr 201222
NCT01477411Drug Interaction Potentiation · United States1CompletedCSLJan 201242
NCT01357811Healthy Volunteer · United States1CompletedSanofiNov 201128
NCT01306175Healthy · Germany1CompletedBoehringer IngelheimApr 201120
NCT01288742Hepatitis C1CompletedJohnson & JohnsonMay 201133
NCT01134965Healthy · Germany1CompletedBoehringer IngelheimJul 201024
NCT00904176Diabetes Mellitus, Type 2 · United States1CompletedAstraZenecaAug 200930
NCT00860223Healthy · United States1CompletedPuma BiotechnologyApr 200927
NCT00831506Alzheimer Disease · United States1CompletedPfizerMay 200912
NCT00712465Atrial Fibrillation · Sweden1CompletedAstraZenecaNov 200818
NCT00650910Breast Neoplasms · United States, Canada, Korea, Republic of1CompletedGlaxoSmithKlineJul 10, 200917

How it is read

Names in the registry

  • “Digoxin”, 33 entries
  • “digoxin”, 6 entries
  • “ZT002 injection, rosuvastatin, digoxin”, 1 entry
  • “Digoxin (0.25mg)”, 1 entry
  • “Lenoxin®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.